Study of RAD001 in Adenoid Cystic Carcinoma

Status Completed

Clinical Trial Summary

- Although mTOR is clearly an attractive therapeutic target in tumor, no clinical study on mTOR inhibition by RAD001 has been systematically conducted in adenoid cystic carcinoma.

- In phase I study of RAD001, 2 patients with adenoid cystic carcinoma show some response to RAD001 (unpublished data).

- So the investigators design this phase II study of RAD001 in adenoid cystic carcinoma to evaluate the efficacy of RAD001 in this orphan disease.

Clinical Trial Description

Although the histologic appearance of adenoid cystic carcinoma is low grade, management of this malignancy is a distinct therapeutic challenge because of its insidious local growth pattern, propensity for perineural involvement, tendency for distant metastasis, and pronounced ability to recur over a prolonged period.

In prospectively performed clinical trials, objective responses to any cytotoxic agent or regimen are infrequent, whereas stabilization of disease was observed more commonly.

In adenoid cystic carcinoma, the study focusing on PI3-K/AKT/mTOR pathway is rare.

According to Younes MN et al's study, adenoid cystic carcinoma cell lines have increased pAkt activity when EGF-stimulation is added. And when treated with EGFR/VEGFR TK dual inhibitor, the phosphorylated form of Akt decreased despite of total level of Akt is remained unchanged.

When the investigators consider that the increased pAkt activity is one of possible predictor to mTOR inhibitor, the mTOR inhibitor might have an activity in adenoid cystic carcinoma.

Although mTOR is clearly an attractive therapeutic target in tumor, no clinical study on mTOR inhibition by RAD001 has been systematically conducted in adenoid cystic carcinoma.

In phase I study of RAD001, 2 patients with adenoid cystic carcinoma show some response to RAD001 (unpublished data).

So the investigators design this phase II study of RAD001 in adenoid cystic carcinoma to evaluate the efficacy of RAD001 in this orphan disease. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01152840
Study type	Interventional
Source	Seoul National University Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	July 2008
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04973683` - AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer	Phase 1
Completed	`NCT01417143` - Dovitinib in Adenoid Cystic Carcinoma	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT05010629` - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma	Phase 2
Recruiting	`NCT04801264` - Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617	Early Phase 1
Completed	`NCT03319641` - PSMA-PET Imaging for Advanced ACC/SDC	N/A
Recruiting	`NCT02942693` - Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT00581360` - Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck	Phase 2
Not yet recruiting	`NCT05553782` - Drug Screening Using Novel IMD in ACC and Salivary Cancers	Early Phase 1
Completed	`NCT04291300` - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT02775370` - A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck	Phase 2
Active, not recruiting	`NCT02780310` - Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT04119453` - A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)	Phase 2
Active, not recruiting	`NCT02098538` - Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT01558661` - Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT01524692` - Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma	Phase 2
Recruiting	`NCT03556228` - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma	Phase 1
Recruiting	`NCT01192087` - Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy	Phase 1/Phase 2
Recruiting	`NCT04209660` - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Phase 2
Recruiting	`NCT05774899` - CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of RAD001 in Adenoid Cystic Carcinoma — ACCRAD001

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms